U

University of Iowa Hospitals | Infectious Diseases Department

Research site
(Unclaimed)
Location
200 Hawkins Dr, Iowa City, Iowa, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

7 of 24
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance tr...

Active, not recruiting
FIGO Stage III-IV
Newly Diagnosed
Drug: Rucaparib
Drug: Placebo Oral Tablet

ASP1002 is a potential new treatment for people with certain solid tumors. Before ASP1002 is available as a treatment, the researchers need to unders...

Active, not recruiting
Advanced Solid Tumors
Drug: ASP1002

ASP2074 is a potential new treatment for people with certain solid tumors. Before ASP2074 is available as a treatment, the researchers need to unders...

Enrolling
Advanced Solid Tumors
Drug: ASP2074

This study will enroll individuals who have:Completed primary series of mRNA COVID-19 vaccine, andAn antibody response ≤ 2500 U/mL measured at least...

Active, not recruiting
Liver Transplant Recipients
Kidney Transplant Recipients
Biological: Moderna COVID-19 Vaccine 2023-2024
Biological: Pfizer-BioNTech COVID-19 Vaccine 2023-2024

The purpose of the trial is to evaluate the safety of acasunlimab (also known as GEN1046) as monotherapy and in combination therapies in patients wit...

Active, not recruiting
Endometrial Carcinoma
Squamous Cell Carcinoma of the Head and Neck
Biological: Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)
Biological: Acasunlimab in combination with docetaxel (in a single expansion cohort)

The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected...

Enrolling
Advanced Unresectable Solid Tumor
Metastatic Solid Tumor
Drug: Toripalimab
Drug: TAB004

The purpose of this study is to evaluate the safety, tolerability, and clinical response of ASP7517, and determine the Recommended Phase 2 Dose (RP2D...

Active, not recruiting
Advanced Cancer
Advanced Malignancies
Drug: Pembrolizumab
Drug: ASP7517

Trial conditions

Cancer (5 trials)
Disorders of Excessive S... (2 trials)
Sleepiness (2 trials)
Acute Myeloid Leukemia (1 trial)
Anemia (1 trial)
Atrophy (1 trial)
Autoimmune Hemolytic Ane... (1 trial)
Carcinoma (1 trial)
Cardiovascular Diseases (1 trial)
Circadian Rhythm Sleep D... (1 trial)

And 26 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems